MedicaidPrior AuthMedium impact
Darzalex Faspro™ (daratumumab and hyaluronidase- fihj) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Jun 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Darzalex Faspro (daratumumab and hyaluronidase-fihj) subcutaneous solution for Ohio Medicaid patients with multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma. Prior authorization is required with specific combination therapy requirements and clinical criteria that must be met for approval.
Action Required
Before June 1, 2026: Billing team must implement prior authorization requirements for Darzalex Faspro subcutaneous solution for Ohio Medicaid patients. Update billing system to flag this medication and create workflow to obtain prior auth before administering. Providers must document specific diagnosis (multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma) and combination therapy details. Claims will be denied without proper prior authorization.